Bristol Myers Squibb Announces Topline Results From Unit RayzeBio's Planned Interim Analysis Of ACTION-1 Trial; RYZ101 Study Met Primary Endpoint With Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival By Blinded Independent Central Review, And Safety Results Consistent With Known Safety Profile

Bristol Myers Squibb (NYSE: BMY) announced positive topline results from the interim analysis of the ACTION-1 trial, indicating that RYZ101 (225Ac-DOTATATE) achieved a statistically significant improvement in progression-free survival for patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study's safety results were consistent with the known safety profile of RYZ101. The FDA had previously granted RYZ101 Orphan Drug Designation for GEP-NETs, and the company plans to engage with the FDA regarding regulatory submission following these results.